Xeris Biopharma(XERS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 43% year-over-year to nearly $86 million, with full-year revenue increasing by 44% to $292 million [5][14] - Adjusted EBITDA for Q4 was $25.1 million, an improvement of $16.8 million compared to the previous year, with full-year adjusted EBITDA at $59.4 million [17][18] - The company reported net income for the first time on a full-year basis in 2025, reflecting improved financial health [18] Business Line Data and Key Metrics Changes - Recorlev revenue was $45.3 million in Q4 and $139.3 million for the full year, reflecting over 100% growth for both periods, driven by an expanding patient base [15][16] - Gvoke generated $24.6 million in Q4 and $94.1 million for the full year, with steady prescription growth and broad access [15][16] - Keveyis revenue was $12.8 million in Q4 and $47.6 million for the year, supported by an increase in the average number of patients on therapy [16] Market Data and Key Metrics Changes - Recorlev ended 2025 with approximately 700 patients, nearly doubling from year-end 2024, indicating strong market demand [6] - Gvoke remains a life-saving product for diabetes patients, with continued alignment with treatment guidelines contributing to its growth [8] - The company anticipates a significant market opportunity for XP-8121, targeting a peak revenue potential of $1 billion to $3 billion [11] Company Strategy and Development Direction - The company aims to drive rapid revenue growth, advance its pipeline, and maintain a strong balance sheet for future investments [11][18] - The strategic focus includes expanding the commercial team for Recorlev and preparing for the Phase 3 study of XP-8121 [10][11] - The company is committed to maintaining disciplined investment prioritization while enhancing operating leverage [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial self-sustainability and the ability to fund its strategy and pipeline [4][5] - The outlook for 2026 includes expected total revenue between $375 million and $390 million, representing over 30% growth at the midpoint compared to 2025 [11][19] - Management highlighted the importance of continued investment in R&D and commercial infrastructure to support growth [20] Other Important Information - The company filed a patent infringement lawsuit against two ANDA filers to protect its rights regarding Recorlev [7] - The company has four Orange Book-listed patents for Recorlev that run until March 2040, providing a strong IP foundation [7] Q&A Session Summary Question: Insights on Recorlev expansion and operating leverage - Management noted the recent doubling of the commercial footprint and the need for additional resources to manage patient loads effectively [25][26] Question: Impact of IP litigation on business development - Management reiterated that their strategy for Recorlev remains unchanged and they are prepared for the ongoing litigation [30][31] Question: Guidance on capital deployment beyond 2026 - Management indicated a strong balance sheet and the potential for business development opportunities, while emphasizing the strength of existing assets [32] Question: Revenue guidance by product for 2026 - Management expects steady contributions from Keveyis and Gvoke, with Recorlev being the primary growth driver [40] Question: Updates on XP-8121 and FDA interactions - Management confirmed alignment with the FDA and emphasized the importance of entering Phase 3 with a scaled-up commercial device [52] Question: Openness to settlement regarding Recorlev litigation - Management declined to comment on legal strategy but expressed confidence in their patent position [66]